Monday, October 11, 1993
Scios Nova Inc.
Jay Silverman of Wertheim Schroder initiated coverage with a "buy" and added it to the firm's Recommended List. Silverman said SCIO's cardiovascular compounds, Auriculin atrial natriuretic peptide and Natrecor
brain natriuretic peptide, have the potential to establish the company as a leader in the treatment of acute cardiovascular diseases. Auriculin could become biotech's most important life-saving drug since tPA, he said.